COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:

Identification of Vascular Disruptor Compounds by Analysis in Zebrafish Embryos and Mouse Embryonic Endothelial Cells

McCollum CW, Conde-Vancells J, Hans C, Vazquez-Chantada M, Kleinstreuer N, Tal T, Knudsen T, Shah SS, Merchant FA, Finnell RH, Gustafsson JÅ, Cabrera R, Bondesson M.
Reproductive Toxicology (2017) DOI: https://doi.org/10.1016/j.reprotox.2016.11.005 PMID: 27838387


Publication


Abstract

To identify vascular disruptor compounds (VDCs), this study utilized an in vivo zebrafish embryo vascular model in conjunction with a mouse endothelial cell model to screen a subset of the U.S. Environmental Protection Agency (EPA) ToxCast Phase I chemical inventory. In zebrafish, 161 compounds were screened and 34 were identified by visual inspection as VDCs, of which 28 were confirmed as VDCs by quantitative image analysis. Testing of the zebrafish VDCs for their capacity to inhibit endothelial tube formation in the murine yolk-sac-derived endothelial cell line C166 identified 22 compounds that both disrupted zebrafish vascular development and murine endothelial in vitro tubulogenesis. Putative molecular targets for the VDCs were predicted using EPA's Toxicological Prioritization Index tool and a VDC signature based on a proposed adverse outcome pathway for developmental vascular toxicity. In conclusion, our screening approach identified 22 novel VDCs, some of which were active at nanomolar concentrations.

Figures


Figure 1. VDCs cause malformed vascular development in the ISV, DA and CVP.

Tg(kdrl:EGFP)mitfab692 embryos were treated with vehicle (control; A, E) or chemicals from the ToxCast Phase 1 chemical library (B-D, F, G) from 3 hpf to 72 hpf. Lateral view with anterior to the left and dorsal to the top. Vascular defects include non-overlapping ISVs (B), or thin and underdeveloped ISVs (C), expanded DA (D), and less condensed CVP (F), or misshapen CVP (G) and are marked with yellow lines or arrows. A common vascular-related phenotype, which is characteristic of cardiotoxicity, is pericardial edema (H; black arrowhead). Scale bar = 100 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Figure 2. C166 cells tube formation is affected by VDCs.

C166 cells assemble into capillary-like structures when grown on Matrigel for 150 min. Angiogenesis analyzer mapping of the mesh network formed by C166 cells growing on Matrigel upon treatment with vehicle (0.1% DMSO) and increasing doses of rotenone for 150 min.

Figure 3. Color map showing minimal concentrations

The color map shows the minimal concentration of each chemical required to affect the parameters measured by angiogenesis analyzer in C166 cells.

Figure 4. pVDC signatures for zebrafish and C166 cell VDCs

Molecular pathways with corresponding in vitro assays used in the ToxCast screening program were selected to build the putative VDC signature (A). Ranking and pVDC signatures of VDCs active both in zebrafish and in C166 cells (B). Ranking and pVDC signatures of chemicals acting as VDCs in either zebrafish or C166 cells (C). Cytokine signaling (red); vessel stabilization (purple), angiogenic signaling (blue); and extracellular matrix (ECM) remodeling (green) quadrants are shown. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Tables


Table 1. Lowest effect levels (LELs) for compounds that cause ISV and PVC perturbations

* Compounds with “No effect” were initially found to cause vascular disruption via visual assessment, but not via automated image analysis. PE = Pericardial edema; BC = Blood clot, accumulation or hemorrhage; CVP = Caudal vein plexus phenotype; ISV = Intersegmental vessel phenotype; DA = Dorsal aorta; PCV = Posterior cardinal vein.

Supplemental Materials


Supplemental Data